ET Pharma

📢 Big Announcement! 📢 The second edition of ET Pharma Next Gen LabCon is coming to Hyderabad on July 26, 2024! 🧬 Get ready for a day filled with innovation, insights, and networking in the world of pharma and biotech. Mark your calendars and stay tuned for more details! 🔬 Know more- https://bit.ly/4537CYM #ETPharma #NextGen #Pharmaceutical #ETLabCon #Pharma #BigData #Compliance #GDPRCompliance #LabCon2024 #PharmaInnovation #NextGenLabCon #HyderabadEvent #BiotechRevolution

Boehringer Ingelheim-GoodRx partner to offer Humira rival at 92% discount A close copy version of Abbvie's blockbuster arthritis drug Humira will be available at a 92% discount to its list price on the GoodRx website, the digital healthcare platform and German drugmaker Boehringer Ingelheim said on Thursday. #biosimilars I #GermandrugmakerBoehringer I #insurancestatus I #validprescription I #pharmacybenefitmanagers Read more: https://lnkd.in/gtBZdg2m

Zydus Group gets FDA nod for diabetes drug Zydus Lifesciences on Friday said it has received approval from the US health regulator for its new drug application for a diabetes medication. The company has received final approval for its new drug application (NDA) from the US Food and Drug Administration (USFDA) to market Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets, the drug firm said in a statement. #ZituvimetXR I #type2diabetesmellitus I #drug I #metforminhydrochloride I #regulatoryapproval I #newdrugapplication Read more: https://lnkd.in/g32z8YvH

Eli Lilly and Company's weight loss drug tirzepatide gets approval in China A spokesperson for Eli Lily did not immediately respond to a request for comment on when its own drug's sales would begin in China or how many doses would be supplied. Tirzepatide is the active ingredient in the U.S. firm's diabetes drug Mounjaro, also approved in China, and weight-loss drug Zepbound. #keyAsianmarket I #weightlossdrug I #Wegovy I #furtherintensifyingompetition I #highestnumberofoverweight I #companiesobesitytreatments Read more: https://lnkd.in/gvMKp-mp

Exciting News! Revvity Signals is our Exhibit Partner at ET Pharma Next Gen LabCon 2024 in Hyderabad on July 26th. Join us in revolutionizing the future of pharmaceutical research and development. Know more- https://bit.ly/4537CYM #ETPharma #ETLabcon #NextGen #Pharmaceutical #LabCon #Pharma #BigData #Compliance #GDPRCompliance #LabCon2024 #PharmaInnovation #NextGenLabCon #HyderabadEvent #BiotechRevolution

Dr. Reddy's Laboratories inks licensing pact with Takeda to sell gastrointestinal drug "The non-exclusive patent licensing agreement with Takeda is part of our continuous efforts to make innovative medicines available to patients in India through strategic collaborations to meet unmet needs and enhance standard of care," Dr Reddy's CEO - Branded Markets (India & Emerging Markets) MV Ramana stated. #Agreement I #gastrointestinaldrug I #licensingpact I #Vonoprazan I #trademark Read more: https://lnkd.in/gFRtKwtm

As Roche blocks Zydus Group’ Pertuzumab launch, experts see murky corporate rivalry An interim injunction from the Delhi High Court paused Zydus Lifesciences’ bid to launch the biosimilars of Roche’s breast cancer drug Perjeta (pertuzumab). But as the story unfolds, experts from multinational companies raised objections around the transparency in the clinical trial process. They also alleged the due process for the biosimilar’s approvals was not followed. Experts from the Indian industry steadfastly refuted Roche’s claims. #biosimilar I #DelhiHighCourt I #breastcancer I #Perjeta I #Pertuzumab I #RocheZyduscorporaterivalry I #Lawsuit I #concealingregulatorymilestones I #API I #Kenya I #Swissdrugmaker I Central Drugs Standard Control Organization I Prabhat Prakash Read more: https://lnkd.in/gqKaAtYR

AUROBINDO PHARMA LTD board approves Rs 750-cr share buyback plan At the end of June 30, the company promoters owned 51.8 per cent stake, while foreign institutional investors (FIIs) and mutual funds owned 16.73 per cent and 19.17 per cent respectively. #sharebuybackplan I #boardapproval I #aggregateamount I #recorddate I #foreigninstitutionalinvestors I #Pharmacompany Read more: https://lnkd.in/gNPsgQxG

Swiss pharma giant Novartis reports soaring profits off drug sales "Our performance reflects continued strong momentum of our key growth drivers" both in and outside the United States, CEO Vas Narasimhan said in the statement. #pharmaceutical I #operatingincome I #drugsales I #Zurich I Vas Narasimhan Read more: https://lnkd.in/gYu9hzh4

We are excited to welcome apna as our Exhibit Partner at ET Pharma Next Gen LabCon 2024 in Hyderabad on July 26th!  Join us as we navigate this analog-to-digital transformation, shaping the future of pharmaceutical research and development. Know more- https://bit.ly/4537CYM #ETPharma #ETLabcon #NextGen #Pharmaceutical #LabCon #Pharma #BigData #Compliance #GDPRCompliance #LabCon2024 #PharmaInnovation #NextGenLabCon #HyderabadEvent #BiotechRevolution